Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma

EHA Congress 2022

9 - 12 Jun 2022

Published: 13 Jun 2022

Views: 79

Rating:

Save

Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain

Dr Carlos Fernandez De Larrea presents data from the multicentre CARTBCMA-HCB-01 study during a press conference at the EHA 2022 meeting.

The study evaluated the efficacy and safety of a novel autologous CAR T-cell product (ARI0002h) targeting B-cell maturation antigen (BCMA) in patients with relapsed/refractory multiple myeloma.

Watch Dr Fernández De Larrea's interview here

Read the news story here

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone...

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...

$Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )$

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment...

Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer ( Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan )

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows...

Dr Emma Searle - University of Manchester, Manchester, UK

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma ( Dr Emma Searle - University of Manchester, Manchester, UK )

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly...

Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly improved PFS for advanced melanoma ( Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )

More from ecancer